Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Metabolic myopathies caused by disorders of lipid and purine metabolism

Basil T Darras, MD
Section Editor
Marc C Patterson, MD, FRACP
Deputy Editor
John F Dashe, MD, PhD


Patients with metabolic myopathies have underlying deficiencies of energy production in muscle due to a wide variety of defects. These include defects in lipid, glycogen, glucose, adenine nucleotide, and mitochondrial metabolism [1].

A discussion of the myopathies resulting from disorders of lipid metabolism (table 1) is presented in this review. These include:

Carnitine deficiency syndromes

Fatty acid transport defects

Defects of beta-oxidation enzymes


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Mar 23, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22:87.
  2. El-Hattab AW. Systemic primary carnitine deficiency. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK84551/ (Accessed on January 22, 2015).
  3. Tobon A. Metabolic myopathies. Continuum (Minneap Minn) 2013; 19:1571.
  4. Sharp LJ, Haller RG. Metabolic and mitochondrial myopathies. Neurol Clin 2014; 32:777.
  5. Lamhonwah AM, Olpin SE, Pollitt RJ, et al. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet 2002; 111:271.
  6. Karpati G, Carpenter S, Engel AG, et al. The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology 1975; 25:16.
  7. Coates PM, Hale DE, Stanley CA, Glasgow AM. Systemic carnitine deficiency simulating Reye syndrome. J Pediatr 1984; 105:679.
  8. Cruse RP, Di Mauro S, Towfighi J, Trevisan C. Familial systemic carnitine deficiency. Arch Neurol 1984; 41:301.
  9. Hale DE, Cruse RP, Engel A. Familial systemic carnitine deficiency. Arch Neurol 1985; 42:1133.
  10. Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy. N Engl J Med 1981; 305:385.
  11. Chapoy PR, Angelini C, Brown WJ, et al. Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med 1980; 303:1389.
  12. El-Hattab AW, Li FY, Shen J, et al. Maternal systemic primary carnitine deficiency uncovered by newborn screening: clinical, biochemical, and molecular aspects. Genet Med 2010; 12:19.
  13. Schimmenti LA, Crombez EA, Schwahn BC, et al. Expanded newborn screening identifies maternal primary carnitine deficiency. Mol Genet Metab 2007; 90:441.
  14. Spiekerkoetter U, Huener G, Baykal T, et al. Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. J Inherit Metab Dis 2003; 26:613.
  15. Amat di San Filippo C, Taylor MR, Mestroni L, et al. Cardiomyopathy and carnitine deficiency. Mol Genet Metab 2008; 94:162.
  16. Li FY, El-Hattab AW, Bawle EV, et al. Molecular spectrum of SLC22A5 (OCTN2) gene mutations detected in 143 subjects evaluated for systemic carnitine deficiency. Hum Mutat 2010; 31:E1632.
  17. Melegh B. [The human OCTN2 carnitine transporter and its mutations]. Orv Hetil 2004; 145:679.
  18. Wang Y, Korman SH, Ye J, et al. Phenotype and genotype variation in primary carnitine deficiency. Genet Med 2001; 3:387.
  19. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: The Metabolic Bases of Inherited Disease, 8th ed, Scriver CR, Beaudet AL, Sly WS, Walle D (Eds), McGraw-Hill, New York 2001. p.2297.
  20. Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004; 1033:42.
  21. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006; 142C:77.
  22. Cano A, Ovaert C, Vianey-Saban C, Chabrol B. Carnitine membrane transporter deficiency: a rare treatable cause of cardiomyopathy and anemia. Pediatr Cardiol 2008; 29:163.
  23. Laforêt P, Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul Disord 2010; 20:693.
  24. Engel AG, Angelini C. Carnitine deficiency of human skeletal muscle with associated lipid storage myopathy: a new syndrome. Science 1973; 179:899.
  25. De Vivo DC, Tein I. Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990; 5:134.
  26. Stanley CA. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv Pediatr 1987; 34:59.
  27. Scholte H, de Jonge P. Metabolism, function and transport of carnitine in health and disease. In: Carnitin in der Medizin, Gitzelman R, Baerlocker K, Steinmann B (Eds), Schattauer, Stuttgart 1987. p.22.
  28. DiDonato S, Taroni F. Disorders of lipid metabolism. In: The Molecular and Genetic Basis of Neurological Disease, Rosenberg RN, Prusiner SB, DiMauro S, et al (Eds), Butterworth-Heinemann, Boston 2003. p.591.
  29. DiMauro S, De Vivo DC. Diseases of carbohydrate, fatty acid and mitochondrial metabolism. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 7th ed, Siegel GJ, Albers RW, Brady ST, Price DL (Eds), Academic Press, Boston 2007. p.695.
  30. Engel A. Carnitine deficiency syndromes and lipid storage myopathies. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1986. p.1663.
  31. Flanagan JL, Simmons PA, Vehige J, et al. Role of carnitine in disease. Nutr Metab (Lond) 2010; 7:30.
  32. Bernardini I, Rizzo WB, Dalakas M, et al. Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 1985; 75:1124.
  33. Ito M, Ikeda Y, Arnez JG, et al. The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta 1990; 1034:213.
  34. Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989; 2:469.
  35. Tein I. Metabolic myopathies. Semin Pediatr Neurol 1996; 3:59.
  36. Elpeleg ON, Joseph A, Branski D, et al. Recurrent metabolic decompensation in profound carnitine palmitoyltransferase II deficiency. J Pediatr 1993; 122:917.
  37. Poll-The B, Duran M, Mousson B, et al. 30th Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Leuven 1992.
  38. Bennett MJ, Santani AB. Carnitine palmitoyltransferase 1A deficiency. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1527/ (Accessed on January 22, 2015).
  39. Brown NF, Mullur RS, Subramanian I, et al. Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme. J Lipid Res 2001; 42:1134.
  40. Innes AM, Seargeant LE, Balachandra K, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000; 47:43.
  41. Falik-Borenstein ZC, Jordan SC, Saudubray JM, et al. Brief report: renal tubular acidosis in carnitine palmitoyltransferase type 1 deficiency. N Engl J Med 1992; 327:24.
  42. Stoler JM, Sabry MA, Hanley C, et al. Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation. J Inherit Metab Dis 2004; 27:679.
  43. Stanley CA, Hale DE, Berry GT, et al. Brief report: a deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992; 327:19.
  44. Pande SV. A mitochondrial carnitine acylcarnitine translocase system. Proc Natl Acad Sci U S A 1975; 72:883.
  45. Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med 2004; 25:521.
  46. Taggart RT, Smail D, Apolito C, Vladutiu GD. Novel mutations associated with carnitine palmitoyltransferase II deficiency. Hum Mutat 1999; 13:210.
  47. Rafay MF, Murphy EG, McGarry JD, et al. Clinical and biochemical heterogeneity in an Italian family with CPT II deficiency due to Ser 113 Leu mutation. Can J Neurol Sci 2005; 32:316.
  48. Anichini A, Fanin M, Vianey-Saban C, et al. Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency. Neurol Res 2011; 33:24.
  49. Vladutiu GD, Quackenbush EJ, Hainline BE, et al. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr 2002; 141:734.
  50. Isackson PJ, Bennett MJ, Lichter-Konecki U, et al. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab 2008; 94:422.
  51. Demaugre F, Bonnefont JP, Colonna M, et al. Infantile form of carnitine palmitoyltransferase II deficiency with hepatomuscular symptoms and sudden death. Physiopathological approach to carnitine palmitoyltransferase II deficiencies. J Clin Invest 1991; 87:859.
  52. Hug G, Bove KE, Soukup S. Lethal neonatal multiorgan deficiency of carnitine palmitoyltransferase II. N Engl J Med 1991; 325:1862.
  53. Olpin SE, Afifi A, Clark S, et al. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis 2003; 26:543.
  54. Kilfoyle D, Hutchinson D, Potter H, George P. Recurrent myoglobinuria due to carnitine palmitoyltransferase II deficiency: clinical, biochemical, and genetic features of adult-onset cases. N Z Med J 2005; 118:U1320.
  55. DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science 1973; 182:929.
  56. Uzel B, Altiparmak MR, Ataman R, Serdengeçti K. Acute renal failure due to carnitine palmitoyltransferase II deficiency. Neth J Med 2003; 61:417.
  57. Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005; 62:37.
  58. Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010; 10:118.
  59. DiMauro S, Papadimitriou A. Carnitine palmitoyltransferase deficiency. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1986. p.1697.
  60. Elpeleg ON, Hammerman C, Saada A, et al. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet 2001; 102:183.
  61. Ørngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 2003; 61:559.
  62. Tein I. Lipid storage myopathies due to fatty acid oxidation defects. In: Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician’s Approach, 2nd ed, Darras BT, Jones HR Jr, Ryan MM, De Vivo DC (Eds), Academic Press, San Diego 2015. p.761.
  63. Roe CR, Sweetman L, Roe DS, et al. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 2002; 110:259.
  64. Roe CR, Yang BZ, Brunengraber H, et al. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 2008; 71:260.
  65. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009; 360:838.
  66. Ørngreen MC, Madsen KL, Preisler N, et al. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology 2014; 82:607.
  67. Tyni T, Pihko H. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr 1999; 88:237.
  68. den Boer ME, Wanders RJ, Morris AA, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 2002; 109:99.
  69. Moore R, Glasgow JF, Bingham MA, et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency--diagnosis, plasma carnitine fractions and management in a further patient. Eur J Pediatr 1993; 152:433.
  70. Stanley CA, Hale DE, Coates PM, et al. Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res 1983; 17:877.
  71. Duran M, Hofkamp M, Rhead WJ, et al. Sudden child death and 'healthy' affected family members with medium-chain acyl-coenzyme A dehydrogenase deficiency. Pediatrics 1986; 78:1052.
  72. Gartner V, McGuire PJ, Lee PR. Child Neurology: medium-chain acyl-coenzyme A dehydrogenase deficiency. Neurology 2015; 85:e37.
  73. Amendt BA, Greene C, Sweetman L, et al. Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and biochemical studies in two patients. J Clin Invest 1987; 79:1303.
  74. Tein I, De Vivo DC, Hale DE, et al. Short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency in muscle: a new cause for recurrent myoglobinuria and encephalopathy. Ann Neurol 1991; 30:415.
  75. Tein I. Fatty acid oxidation and associated defects. In: Proceedings of the American Academy of Neurology, Omnipress, Seattle 1995. p.9.
  76. Angle B, Burton BK. Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II. Mol Genet Metab 2008; 93:36.
  77. Wilson GN, de Chadarévian JP, Kaplan P, et al. Glutaric aciduria type II: review of the phenotype and report of an unusual glomerulopathy. Am J Med Genet 1989; 32:395.
  78. Grünert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis 2014; 9:117.
  79. Liang WC, Ohkuma A, Hayashi YK, et al. ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscul Disord 2009; 19:212.
  80. Liewluck T, Mundi MS, Mauermann ML. Mitochondrial trifunctional protein deficiency: a rare cause of adult-onset rhabdomyolysis. Muscle Nerve 2013; 48:989.
  81. Boutron A, Acquaviva C, Vianey-Saban C, et al. Comprehensive cDNA study and quantitative analysis of mutant HADHA and HADHB transcripts in a French cohort of 52 patients with mitochondrial trifunctional protein deficiency. Mol Genet Metab 2011; 103:341.
  82. Spiekerkoetter U, Bennett MJ, Ben-Zeev B, et al. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve 2004; 29:66.
  83. Schaefer J, Jackson S, Dick DJ, Turnbull DM. Trifunctional enzyme deficiency: adult presentation of a usually fatal beta-oxidation defect. Ann Neurol 1996; 40:597.
  84. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007; 130:2037.
  85. DiMauro S, Garone C, Naini A. Metabolic myopathies. Curr Rheumatol Rep 2010; 12:386.
  86. Bruno C, Bertini E, Di Rocco M, et al. Clinical and genetic characterization of Chanarin-Dorfman syndrome. Biochem Biophys Res Commun 2008; 369:1125.
  87. Fischer J, Lefèvre C, Morava E, et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 2007; 39:28.
  88. Reilich P, Horvath R, Krause S, et al. The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene. J Neurol 2011; 258:1987.
  89. Massa R, Pozzessere S, Rastelli E, et al. Neutral lipid-storage disease with myopathy and extended phenotype with novel PNPLA2 mutation. Muscle Nerve 2016; 53:644.
  90. Akman HO, Davidzon G, Tanji K, et al. Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. Neuromuscul Disord 2010; 20:397.
  91. Ohkuma A, Noguchi S, Sugie H, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle Nerve 2009; 39:333.
  92. Michot C, Hubert L, Brivet M, et al. LPIN1 gene mutations: a major cause of severe rhabdomyolysis in early childhood. Hum Mutat 2010; 31:E1564.
  93. Michot C, Hubert L, Romero NB, et al. Study of LPIN1, LPIN2 and LPIN3 in rhabdomyolysis and exercise-induced myalgia. J Inherit Metab Dis 2012; 35:1119.
  94. Bergounioux J, Brassier A, Rambaud C, et al. Fatal rhabdomyolysis in 2 children with LPIN1 mutations. J Pediatr 2012; 160:1052.
  95. Han GS, Wu WI, Carman GM. The Saccharomyces cerevisiae Lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme. J Biol Chem 2006; 281:9210.
  96. Harris TE, Finck BN. Dual function lipin proteins and glycerolipid metabolism. Trends Endocrinol Metab 2011; 22:226.
  97. Fishbein WN. Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 1985; 33:158.
  98. Sabina RL, Swain JL, Olanow CW, et al. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J Clin Invest 1984; 73:720.
  99. Sabina RL, Morisaki T, Clarke P, et al. Characterization of the human and rat myoadenylate deaminase genes. J Biol Chem 1990; 265:9423.
  100. Genetta T, Morisaki H, Morisaki T, Holmes EW. A novel bipartite intronic splicing enhancer promotes the inclusion of a mini-exon in the AMP deaminase 1 gene. J Biol Chem 2001; 276:25589.
  101. Abe M, Higuchi I, Morisaki H, et al. Myoadenylate deaminase deficiency with progressive muscle weakness and atrophy caused by new missense mutations in AMPD1 gene: case report in a Japanese patient. Neuromuscul Disord 2000; 10:472.
  102. Morisaki T, Gross M, Morisaki H, et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci U S A 1992; 89:6457.
  103. Morisaki H, Higuchi I, Abe M, et al. First missense mutations (R388W and R425H) of AMPD1 accompanied with myopathy found in a Japanese patient. Hum Mutat 2000; 16:467.
  104. Sabina RL, Ogasawara N, Holmes EW. Expression of three stage-specific transcripts of AMP deaminase during myogenesis. Mol Cell Biol 1989; 9:2244.
  105. Morisaki H, Morisaki T, Newby LK, Holmes EW. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J Clin Invest 1993; 91:2275.
  106. Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.
  107. Baumeister FA, Gross M, Wagner DR, et al. Myoadenylate deaminase deficiency with severe rhabdomyolysis. Eur J Pediatr 1993; 152:513.
  108. Sabina RL. Myoadenylate deaminase deficiency. A common inherited defect with heterogeneous clinical presentation. Neurol Clin 2000; 18:185.
  109. Fishbein WN, Griffin JL, Armbrustmacher VW. Stain for skeletal muscle adenylate deaminase. An effective tetrazolium stain for frozen biopsy specimens. Arch Pathol Lab Med 1980; 104:462.